Registered title, quoted from ClinicalTrials.gov
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
An open trial on spinal muscular atrophy, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 3 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteChildren's Hospital of Fudan University复旦大学附属儿科医院ShanghaiHospital page
- Study siteChildren's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院HangzhouHospital page
- Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07554924, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 1
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (1 points)Hide the checklist
Not stated to 180 days; sex: all
Registered eligibility fields
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07554924, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Type I SMA, defined by bi-allelic mutations in the SMN1 gene.
- Clinical history and signs are consistent with type I SMA, such as hypotonia, delayed motor function development, and poor head control.
- On the day of administration, the age of the subjects do not exceed 180 days after birth.
Exclusion Criteria:
- Pulse oximetry < 96% saturation at screening while the patient is awake or asleep without any supplemental oxygen or respiratory support.
- Weight-for-age below the 3rd percentile for the same sex and age based on WHO Child Growth Standards.
- Active viral infection.
- In the presence of other severe infections or diseases that require systemic anti-infection treatment.
- Known allergy to prednisolone, other glucocorticoids, or SKG0201's excipients.
- Clinically significant abnormal laboratory values prior to administration.
- Previously used Zolgensma or other SMA gene therapy drugs, or currently participating in other SMA clinical studies on therapeutic drugs.
- Having previously undergone major surgery or expected to undergo major surgery during the study assessment period.
Quoted from ClinicalTrials.gov, NCT07554924, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07554924, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.